Evidence map›Paper›PMID 20943311›Full record

ReviewCancer letters2011

miRNAs in the pathogenesis of oncogenic human viruses.

Zhen Lin, Erik K Flemington

Abstract readReview
In one paragraph

Review in Cancer letters, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed, 1 pooled it
2.7field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 1 synthesis or guideline pooled it, 59 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Zhen LinDepartment of Pathology, SL-79, Tulane Health Sciences Center, 1430 Tulane Avenue, New Orleans, LA 70112, USA.
Erik K Flemington
Tulane University · US

Funding

Analysis of Epstein Barr virus type III latency on cellular miRNA gene expressionR01CA130752 · NCI · TULANE UNIVERSITY OF LOUISIANA · PI FLEMINGTON, ERIK K · 2008 to 2012
$1.7M
Role of the cellular microRNA, miR-155, in EBV type III latency signalingR01CA138268 · NCI · TULANE UNIVERSITY OF LOUISIANA · PI FLEMINGTON, ERIK K · 2009 to 2013
$1.5M
Regulation of Epstein Barr virus reactivation through the co-activators, CBP/p300R01CA124311 · NCI · TULANE UNIVERSITY OF LOUISIANA · PI FLEMINGTON, ERIK K · 2007 to 2011
$1.3M
NCI NIH HHS R01 CA124311NCI NIH HHS R01 CA130752NCI NIH HHS R01 CA138268
6 · The paper itself

Abstract

Tumor viruses are a class of pathogens with well established roles in the development of malignant diseases. Numerous bodies of work have highlighted miRNAs (microRNAs) as critical regulators of tumor pathways and it is clear that the dysregulation of cellular miRNA expression can promote tumor formation. Tumor viruses encode their own miRNAs and/or manipulate the expression of cellular miRNAs to modulate their host cell environment, thereby facilitating their respective infection cycles. The modulation of these miRNA responsive pathways, however, often influences certain signal transduction cascades in ways that favor tumorigenesis. In this review, we discuss the roles of virally-encoded and virally-regulated cellular miRNAs in the respective viral life cycles and in virus associated pathogenesis.

Indexed as

AnimalsGene SilencingHerpesvirus 4, HumanHerpesvirus 8, HumanHumansMicroRNAsModels, BiologicalNeoplasmsOncogenic VirusesSignal TransductionVirus DiseasesMicroRNAsMIRN146 microRNA, humanMIRN155 microRNA, human

Identifiers

PMID20943311
PMCPMC3023823
OpenAlexW2012418332

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.